Abstract
BackgroundAfter the expiration of bio-originators’ licenses, the development of less expensive biosimilars has prompted the switch to these drugs. Data on the switch from etanercept (ETA) bio-originators to biosimilars are...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have